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Rab geranylgeranyl transferase (RGGT) catalyzes the post-
translational geranylgeranyl (GG) modification of (usually) two
C-terminal cysteines in Rab GTPases. Here we studied the
mechanism of the Rab geranylgeranylation reaction by bisphos-
phonate analogs in which one phosphonate group is replaced by
a carboxylate (phosphonocarboxylate, PC). The phosphonocar-
boxylates used were 3-PEHPC, which was previously reported,
and 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopro-
pionic acid (()-3-IPEHPC), a >25-fold more potent related
compound as measured by both IC50 and Ki. ()-3-IPEHPC
behaves as amixed-type inhibitor with respect to GG pyrophos-
phate (GGPP) and an uncompetitive inhibitor with respect to
Rab substrates. We propose that phosphonocarboxylates pre-
vent only the secondGG transfer onto Rabs based on the follow-
ing evidence. First, geranylgeranylation of Rab proteins ending
with a single cysteine motif such as CAAX, is not affected by the
inhibitors, either in vitro or in vivo. Second, the addition of an
-AAX sequence onto Rab-CC proteins protects the substrate
from inhibition by the inhibitors. Third, we demonstrate
directly that in thepresenceof ()-3-IPEHPC,Rab-CCandRab-
CXC proteins are modified by only a single GG addition. The
presence of ()-3-IPEHPC resulted in a preference for the Rab
N-terminal cysteine to be modified first, suggesting an order of
cysteine geranylgeranylation inRGGTcatalysis.Our results fur-
ther suggest that the inhibitor binds to a site distinct from the
GGPP-binding site on RGGT. We suggest that phosphonocar-
boxylate inhibitors bind to a GG-cysteine binding site adjacent
to the active site, which is necessary to align the mono-GG-Rab
for the second GG addition. These inhibitors may represent a
novel therapeutic approach in Rab-mediated diseases.
Most proteins of the Ras-like GTPase superfamily need to be
post-translationallymodified by prenyl groups to associatewith
cellular membranes and to activate downstream effectors (1).
Protein prenylation involves the formation of a thioether link
between conserved C-terminal cysteines in protein substrates
and farnesyl pyrophosphate (FPP)7 or geranylgeranyl pyro-
phosphate (GGPP) (2, 3). These prenyl pyrophosphates, which
originate from the mevalonate pathway are utilized by three
different prenyltransferase enzymes (2, 3). Farnesyl transferase
(FT) and geranylgeranyl transferase type I (GGT-I) transfer FPP
or GGPP, respectively, to a cysteine residue in the context of a
C-terminal CAAXmotif, where C is a cysteine,A is an aliphatic
residue, and X is any amino acid. X contributes significantly to
substrate specificity in FT and GGT-I (2). Rab geranylgeranyl
transferase (RGGT) is distinct from FT and GGT-I in that it
specifically recognizes Rab proteins, which vary in their C ter-
minus containing CCXX, XCXC, XXCC, CCXXX, CAAX, and
other motifs (3). RGGT exhibits exquisite specificity for Rabs
due to the strict requirement of Rab escort protein (REP), which
is a general Rab-GDP binding protein (4). RGGT is a het-
erodimeric enzyme consisting of a 60-kDa -subunit and a
38-kDa -subunit, and shares 30% homology with its FT and
GGT-I counterparts (5). The-subunit associateswith REP in a
very small area compared with the entire surface occupied by
the complex, whereas the -subunit binds one molecule of
GGPP in a large hydrophobic cavity (5, 6).
Although a large number of specific FT andGGT-I inhibitors
have been developed as potential anti-cancer agents (7, 8), few
inhibitors of RGGT exist. Recently the phosphonocarboxylate
3-PEHPC was identified as a specific RGGT inhibitor, thereby
selectively preventing the prenylation of Rab proteins in cells (9,
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10). This compound was derived from the bisphosphonate,
risedronate, which is used clinically in the treatment of osteo-
porosis, due to its ability to potently inhibit the activity of bone-
resorbing osteoclasts (11). Although bisphosphonates such as
risedronate prevent Rab prenylation, they do not act by inhib-
iting RGGT. Rather, these drugs prevent the synthesis of FPP
and GGPP by inhibiting FPP synthase, thereby preventing all
protein prenylation (12). 3-PEHPC is a weak RGGT inhibitor
and consequently a weak inhibitor of bone resorption. How-
ever, we have recently identified a similar phosphonocarboxy-
late, ()-3-IPEHPC,which is at least 25 timesmore potent than
3-PEHPC as an inhibitor of RGGT.Here, we report the surpris-
ing finding that phosphonocarboxylate inhibitors of RGGT act
by inhibiting only the second Rab geranylgeranylation event,
therefore providing specificity toward Rab proteins with a dou-
ble cysteine C-terminal motif.
EXPERIMENTAL PROCEDURES
Plasmid Constructs—Human REP1 cDNA was cloned into
pFastBacHTb and produced as described previously (13). Rat
RGGT was prepared as described previously (13). Canine
Rab1a, human Rab27a, human Rab5a, human Rab18, and
human Rab6a were amplified by PCR and cloned into pET14b
and human Rab13 and mouse Rab23 were cloned into pGEX-
4T-1 as described previously (14). The indicated C-terminal
sequence mutants were obtained by using the QuikChange
mutagenesis kit (Stratagene). The sequences of all plasmid con-
structs used were confirmed by DNA sequencing.
Recombinant Proteins—The recombinant proteins RGGT
and REP1 were prepared by infection of Sf9 cells with recombi-
nant baculoviruses encoding each subunit of the desired
enzyme and purified by nickel-Sepharose affinity chromatogra-
phy as described previously (13, 15). Recombinant His6 and
glutatathione S-transferase-tagged Rab proteins were purified
by nickel-Sepharose or glutathione-Sepharose affinity as
described previously (16, 17). All recombinant proteins were
snap frozen in small aliquots and stored at80 °C until use.
Bisphosphonates—2-Hydroxy-2-phosphono-3-pyridin-3-
yl-propionic acid (3-PEHPC, previously referred to as NE-10790)
(Structure 1) was a gift from Procter & Gamble Pharmaceuti-
cals. 2-Hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphono-
propionic acid (3-IPEHPC) (Structure 2) was synthesized and
resolved into its component enantiomers by methods reported
elsewhere.8 The ()-enantiomer was used in the present study,
because this has been shown to be selective toward RGGT, and
a more potent inhibitor of this enzyme than the ()-enanti-
omer.8 The enantiopurity was determined to be98% by chiral
HPLC using a Prontosil AX QN (eluted isocratically with 0.7 M
TEAA buffer containing 75%MeOH at pH 5.8; UV detection at
265 nm, flow rate 3ml/min).8 Themore active ()-enantiomer
elutes first. The specific optical rotation []D25 109° was
measured on a Jasco J100 Polarimeter (Structures 1 and 2).
In Vitro Prenylation Assay—RGGT activity was measured by
determining the amount of [3H]GGPP transferred to Rab pro-
teins (15, 18). Unless otherwise indicated, the standard reaction
mixture contained the following concentrations in a final vol-
ume of 25 l: 50 mM sodium HEPES (pH 7.2), 5 mM MgCl2, 1
mMNonidet P-40, 1 mM dithioerythritol, 5M [3H]GGPP (spe-
cific activity 800 dpm/pmol), 4 M Rab proteins, 2 M REP1,
and 50 nM RGGT. After 20 min at 37 °C, the reaction was
stopped by addition of 1 ml of ethanol/HCl (9:1) and the incor-
porated radioactivity was measured by filtration on glass fiber
followed by scintillation counting (18).
Kinetic Analyses—For the inhibition pattern experiments
with biphosphonate compounds, data were collected for times
where product accumulation was linear. The observed initial
velocity data were fitted to Equation 1 for mixed-type inhibi-
tion,whereKm is theMichaelis constant for the varied substrate
S, and Ki is the mixed-type inhibition constant for ()-3-IPE-
HPC and 3-PEHPC.
1
v

Km
Vmax
1 lKi 1S 1Vmax 1 lKi (Eq. 1)
For uncompetitive inhibition the observed initial velocity data
were fitted to Equation 2.
1
v

Km
Vmax
1
S

1
Vmax
1 lKi (Eq. 2)
The Ki and associated S.E. for ()-3-IPEHPC and 3-PEHPC
were calculated using shared parameter curve fitting for all
inhibitor concentrations using the average of duplicate deter-
minations. The error represents the divergence between fitted
curves.
Proteolytic Digestion of Prenylated Rab Proteins and Peptide
Analysis—The peptides were prepared essentially as described
previously (19, 20). The RGGT mixture (25 l), 2 M REP1, 50
nM RGGT, 5 M Rab proteins, 5 M GGPP (specific activity
1600 dpm/pmol) was precipitated by addition of cold acetone
(1 ml) for 1 h at 4 °C. The pellet was washed with 1 ml of cold
acetone and resuspended in 100 l of 25 mM Tris-HCl (pH 8),
4% CHAPS, 1 mM EDTA, and 3 g of endoproteinase C-Lys
(Roche Applied Science) and incubated overnight at 37 °C. The
resulting peptides were isolated on a reverse-phase RPC
8 C. E. McKenna, F. Coxon, I. Mallard-Favier, K. M. Blazewska, J. M. Bala, M. W.
Lundy, F. H. Ebetino, R. A. Baron, M. C. Seabra, M. S. Marma, B. A. Kashemi-
rov, and M. Rogers, manuscript in preparation.
STRUCTURE 1
STRUCTURE 2
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C2/C18 SC 2.1/10 column (GE Healthcare) using a SMART
System chromatography instrument (GE Healthcare). The col-
umn was equilibrated in MilliQ water with 0.06% trifluoroace-
tic acid at room temperature at a flow rate of 200 l/min. 50 l
of sample were injected and the peptides were separated by a
3.5-ml linear gradient (0–70% acetonitrile) and 2.5 ml of 100%
acetonitrile (0.056% trifluoroacetic acid). The radioactivity in
each fraction (200 l) was measured by scintillation counting
(Beckman LS 6000SC).
[3H]GGPP Binding to RGGT—The reaction mixture (25 l),
2 M REP1, 100 nM RGGT, 4 M Rab proteins, 2 M [3H]GGPP
(specific activity  4500 dpm/pmol), and 100 M ()-3-IPE-
HPCwere incubated for 20min at 37 °C andmixed with 2l of
rabbit anti-RGGT (H492) plus 25 l of protein G beads (GE
Healthcare). The solution was gently shaken for 2 h at 4 °C. The
beads were washed 4 times with 1 ml of phosphate-buffered
saline and the proteins were precipitated by adding 200 l of
EtOH/HCl (9:1). The samples were centrifuged at 20,000  g
for 10 min and the radioactivity in 200 l of supernatant was
determined by scintillation counting.
Analysis of Prenylation of GFP-Rabs in 293 Cells—Human
embryonic kidney 293 (293) cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf
serum and seeded into 12-well plates at 2 105 cells/well. The
following day, cells were transfected with 400 ng of purified
plasmids (the epidermal growth factor protein-Rab constructs
detailed above) using FuGENE 6 transfection reagent, accord-
ing to the manufacturer’s instructions (Roche). Immediately
after transfection, 0–1.5mM3-PEHPCwas added to the culture
medium and cells incubated for 24 h. Cells were then lysed in
Triton X-114 fractionation buffer, and prenylated Rabs sepa-
rated fromunprenylatedRabs as previously described (9). 30g
of fractionated lysates (aqueous and detergent-rich phases,
containing unprenylated and prenylated Rabs, respectively)
were electrophoresed on 12% polyacrylamide Criterion gels
(Bio-Rad), transferred to polyvinylidene difluoride membrane,
thenWestern blotted forGFP-Rabs using an anti-GFP antibody
and also -actin as a loading control (Sigma). Bands were visu-
alized following hybridization with secondary antibodies con-
jugated to Alexa Fluor-680 andAlexa Fluor-800 using anOdys-
sey infra red imaging system (LiCor).
Analysis of Localization of GFP-Rabs in 293 Cells—293 cells
were seeded onto 9-mm glass coverslips in 48-well plates at 4
104 cells/well, then transfected the following day with 100 ng of
epidermal growth factor protein-Rab constructs using
FuGENE 6. In some cases, cells were also incubated with 1 mM
3-PEHPC. Cells were incubated for 24 h, then fixed in 4% form-
aldehyde. Nuclei were counterstained with TO-PRO-3 iodide
and the cells were examined using a Zeiss LSM510META con-
focal microscope after mounting the coverslips onto glass
slides.
Isoprenyl Cysteine Methyltransferase (ICMT) Assay—En-
riched ICMT membranes were a kind gift of Patrick J. Casey
(Department of Pharmacology, Duke University). The methyl-
ation of Rab1a was measured after in vitro prenylation of the
protein. The final volume on prenylation reaction (25 l) con-
tains: 50 mM sodium HEPES (pH 7.2), 5 mM MgCl2, 1 mM
dithioerythritol, 20M coldGGPP, 10MRab1a proteins, 2M
REP1, 100 nM RGGT, and 100M ()-3-IPEHPC. After 30min
at 37 °C, 5 l of buffer (50 mM sodium HEPES (pH 7.2), 5 mM
MgCl2, 1 mM dithioerythritol, 10 M [3H]S-adenosylmethi-
onine (specific activity 650 dpm/pmol)) and 1g of enriched
ICMT membranes were added for 40 min. The reaction was
stopped and treated as described previously.
RESULTS
PCs Are Mixed-type Inhibitors of RGGT—We previously
reported weak RGGT inhibition by a racemic phosphonocar-
boxylate compound, 3-PEHPC (10). The pyridine cycle of this
compound was replaced by an imidazo[1,2-a]pyridine cycle to
create ()-3-IPEHPC, a PC analog of the bisphosphonate,
minodronate. We found that ()-3-IPEHPC was 25-fold more
potent for RGGT inhibition compared with 3-PEHPC using
Rab1a as the substrate (IC50 ()-3-IPEHPC  1.3  0.22 M;
IC50 3-PEHPC 31.9 2.1 M; Table 1 and Fig. 1). To assess
the inhibition type with respect to both substrates, Rab and
FIGURE 1. Inhibition of RGGT activity by phosphonocarboxylates. Final
concentrations for the reaction mixture are REP1 (2 M), RGGT (50 nM), GGPP
(5 M), Rab1a (4 M) and increasing concentrations of ()-3-IPEHPC (E) and
3-PEHPC (F). The reactions were incubated for 20 min at 37 °C. The values
represent themeans determined fromduplicate determinations of two inde-
pendent experiments. This experiment is representative of two other inde-
pendent experiments.
TABLE 1
IC50 values for RGGT inhibition by ()-3-IPEHPC and 3-PEHPC
The values represent themean S.E. determined from duplicate determinations of
at least two independent experiments.
Rab substrate IC50()-3-IPEHPC 3-PEHPC
M
Rab1a-CC (WT) 1.27 0.24 31.85 2.13
Rab1a-CSC 1.11 0.30 NDa
Rab1a-CS 221.25 11.49 2000
Rab1a-SC 187.82 8.30 2000
Rab1a-CCS 0.91 0.25 ND
Rab27a-CGC (WT) 0.83 0.50 32.68 1.95
Rab27a-CVLS 800 2000
Rab5a-CCSN (WT) 0.43 0.06 43.47 9.85
Rab5a-CCQNI 16.52 4.42 2000
Rab5a-CCVLL 5.91 0.50 860 80
Rab5a-CVLL 800 2000
Rab6a-CSC 27.22 2.28 1592 95
Rab13-CSLG (WT) 800 2000
Rab18-CSVL (WT) 800 2000
Rab23-CSVP (WT) 800 2000
aND, not determined.
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GGPP, we designed kinetic experiments using ()-3-IPEHPC.
Double-reciprocal plots obtained from such experiments are
shown in Fig. 2A for Rab and Fig. 2B for GGPP. Equations
describing competitive, noncompetitive, uncompetitive, and
mixed-type inhibitions were fitted to the data for Rab1a, result-
ing in a best fit for an uncompetitive inhibition (Fig. 2A); the
calculated Ki under the conditions employed in this assay was
0.21 0.09 M. Similar analysis for the lipid substrate, GGPP,
suggests amixed-type inhibition, i.e. the inhibitor behaves both
as competitive and noncompetitive inhibitor (Fig. 2B); we cal-
culated that Ki  0.074  0.029 M. Interestingly, 3-PEHPC
gave a similar type of inhibition for both substrates with Ki
values of 5  0.18 and 33.6  11.1 M for GGPP and Rab1a
substrates, respectively (Table 2).
Inhibition of Rab Prenylation by PCs Is Dependent on the
C-terminal Prenylation Motif—The velocity of the prenylation
reaction can be described as vt  v1  v2, where vt is the total
velocity of the reaction and v1 and v2 the velocities for the addi-
tion of the first and second GGPP, respectively. To assess the
possibility that different forms of the enzyme-substrate com-
plex are unequally sensitive to ()-3-IPEHPC, we measured
IC50 values for Rab1a substrates with different C-terminal
motifs. To generate mono-prenylated or di-prenylated prod-
ucts at different C-terminal positions, the -CC motif of Rab1a
was replaced by CSC, CCS, CS, or SC, and the respective
recombinant proteins were produced as His-tagged fusion pro-
teins in Escherichia coli and purified. In vitro prenylation assays
were then performed with those substrates at different inhibi-
tor concentrations (Table 1). The IC50 values generated for
Rab1a-CC, Rab1a-CSC, and Rab1a-CCS proteins were very
similar, at around 1M. This result suggests that different dou-
ble-cysteine motifs in the context of the same Rab does not
affect significantly the inhibition by ()-3-IPEHPC. Con-
versely, the IC50 variedwith the Rab substrate used. Comparing
different Rab proteins containing double cysteinemotifs, Rab1a
(CC), Rab5a (CCSN), Rab6a (CSC), and Rab27a (CGC), we
observed a 30-fold higher IC50 for Rab6 as compared with
Rab1a, Rab5a, and Rab27a (Table 1). Similar differences were
found when we measured IC50 values for 3-PEHPC, which was
50-fold higher for Rab6 substrate compared with Rab27a.
We next determinedwhether other factors in the C-terminal
motif affected the inhibitory properties of PCs. In the context of
Rab5a (CCSN), changing to -CCQNI (present in Rab11a),
resulted in an increase in IC50 from 0.4 to 16.5 M for ()-3-
IPEHPC (Table 1), whereas when the motif was changed to
CCVLL, the IC50 was increased to a lesser extent (IC50  5.9
M) (Table 1). Similar differences were found using ()-3-
IPEHPC as the inhibitor (Table 1). Both C-terminal modified
Rab5 proteins were doubly geranylgeranylated as verified by
chromatography as described below (data not shown). The spa-
tial alignment of the CCVLL and CCQNI sequences showed
high similarity in terms of surface area and length, but the
CCQNI sequence was much more hydrophilic than CCVLL
(the grand average of hydropathy coefficients orGRAVYare 0.5
and 3.36, respectively). Therefore, the length and the polarity of
the C-terminal prenylation motif is an important factor in
influencing the inhibitory properties of PCs.
Surprisingly, ()-3-IPEHPC no longer behaved as an inhib-
itor when single cysteine Rabs were used in the assay.We stud-
ied three wild-type proteins, Rab13 (CSLG, as a glutatathione
S-transferase fusion), Rab18 (CSVL, as a glutatathione S-trans-
ferase fusion), and Rab23 (CSVP), and in all three cases no sig-
nificant inhibition was obtained with ()-3-IPEHPC concen-
trations of up to 800 M (Table 1). Consistently, both Rab5a
(Rab5aCVLL) and Rab27a (Rab27aCVLL) single cysteine
FIGURE 2. Characterization of the inhibition of RGGT by ()-3-IPEHPC.
A, Lineweaver-Burk plot for the inhibitionof RGGTby ()-3-IPEHPCwhen Rab1a
was the varied substrate. Prenylation assays (see “Experimental Procedures”)
were carried out in the presence of a fixed concentration of GGPP substrate (5
M) and the indicated concentrations of Rab1a at 0 (F), 0.75 (E), or 2 M ()
()-3-IPEHPC. Data were fit to Equation 1. B, Lineweaver-Burk plot for the
inhibition of Rab1a prenylation when GGPP was the varied substrate. RGGT
assays (see above)were carriedout in thepresenceof a fixed concentrationof
Rab1a substrate (4M) and the indicated concentrations of GGPP at 0 (F), 0.5
(E), or 1M () ()-3-IPEHPC. Datawere fitted to Equation 1. For both panels,
data represent the means of duplicate determinations from a single experi-
ment that is representative of three such experiments.
TABLE 2
Experimental kinetic constants for RGGT inhibition by ()-3-IPEHPC
and 3-PEHPC
The values represent the means  S.E. determined from duplicate determinations
of three independent experiments.
Inhibitor SubstrateRab1a GGPP
()-3-IPEHPC Uncompetitive Mixed-type
Ki 0.211 0.091 M Ki 0.074 0.029 M
3-PEHPC Uncompetitive Mixed-type
Ki 33.56 11.05 M Ki 5 0.18 M
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mutants showed the same pattern (Table 1). Furthermore,
Rab1a mutants with a single prenylatable cysteine (Rab1a-CS
and Rab1a-SC) exhibited a 100-fold increase in IC50 values for
()-3-IPEHPC when used as substrates (221 11 and 187 8
M, respectively) as compared with the wild-type Rab1a-CC
(Table 1). These results indicate that the C-terminal sequence
of the Rab substrates plays a critical role in determining suscep-
tibility to inhibition by PCs, with the mono-geranylgeranylated
(mono-GG) Rab proteins unaffected, or only partially affected
by the compound, and suggest that the first event of prenylation
(v1) is not affected by the inhibitor. This model could also
explain why ()-3-IPEHPC behaved as a mixed-type inhibitor.
The compound may act differently for each prenylation reac-
tion, v1 and v2, i.e. the different transition states for single and
double prenylation.
PCs Inhibit Only the Second Event of Prenylation—To test
our hypothesis that only the second prenylation event is inhib-
ited by ()-3-IPEHPC, we developed a chromatographic
method to discriminate betweenmono-geranylgeranylated and
di-geranylgeranylated forms of Rab proteins. Initially, we
defined the elution volumes of mono-geranylgeranylated and
di-geranylgeranylated peptides. We subjected Rab1a-CC,
Rab1a-CS, and Rab1a-SC to in vitro prenylation and the prod-
ucts of the reaction were digested by endoproteinase C-Lys.
The peptides obtained were separated on a C2/C18 reverse
phase column with an acetonitrile/water gradient and the elu-
tion of [3H]GGPP-labeled fractions was analyzed (Fig. 3).
Under the conditions of the experiment, a clear separation was
achieved between mono- and di-geranylgeranylated peptides.
The Rab1a-CC digestion profile showed a single peak eluting at
95% acetonitrile (fraction 24), whereas the Rab1a-CS and SC
peptides eluted as a single peak at 75% acetonitrile (fraction 18)
(Fig. 3). Then, we performed in vitro prenylation reactions with
Rab1a-CC in the presence or absence of ()-3-IPEHPC at a
saturating concentration (100 M). Strikingly, in the presence
of ()-3-IPEHPC, the di-geranylgeranylated peak disappeared,
whereas a peak corresponding to mono-geranylgeranylated
peptide appeared (Fig. 3). Moreover, an identical profile was
obtained when Rab1a-CSC or Rab5 (CCSN) were used as sub-
strates, as well as when the proteins were digested with trypsin
instead of endoproteinase C-Lys (data not shown). Further-
more, we detectedmono-GGproteins when RGGTwas treated
with 3-PEHPC, similar to the results obtained with ()-3-IPE-
HPC (data not shown). These results clearly indicate that only
the second prenylation event is inhibited by PC compounds,
and that the C-terminal ending of Rab proteins is a critical
determinant of susceptibility to inhibition.
()-3-IPEHPC Does Not Preclude GGPP Binding to RGGT—
Based on the competition experiments, the inhibitor should not
compete for substrate binding to RGGT, or only partially in
case of GGPP. To assess the association of GGPP with the
enzyme, we performed in vitro prenylation assays with or with-
out ()-3-IPEHPC. Then, we analyzed GGPP molecules asso-
ciated with RGGT by immunoprecipitation of the enzyme
using protein-G beads coupled to rabbit anti-RGGT antibody.
Excess GGPP was removed by extensive washing of the beads.
The RGGT-bound GGPP was then separated from Rab-GG by
methanol extraction as Rab-GG precipitates under these con-
ditions. In the absence of inhibitor, RGGT-bound GGPP was
isolated when no Rab substrate was added, consistent with the
existence of a stable GGPP binding site (Fig. 4). As the yield of
enzyme after immunoprecipitation is 	50%, 	80% of RGGT
was loaded with radiolabeled GGPP under these conditions
(Fig. 4). This RGGT-bound GGPP disappeared in the presence
of Rab1a-CC, but not in the presence of Rab1a-CS (Fig. 4).
These results suggested that the inability to doubly gera-
nylgeranylate Rab1a-CS ledGGPP to remain stuck in theGGPP
FIGURE 3. C18 reverse-phase HPLC analysis of [3H]GG-labeled Rab1a
tryptic peptides. Rab1a-CC (F), Rab1a-CS (E), Rab1a-SC (), and Rab1a-CC
 ()-3-IPEHPC (100 M) (‚) were incubated separately with [3H] GGPP and
RGGT/REP1, and digested with endoproteinase C-Lys. The respective diges-
tion mixtures were then purified by reverse-phase HPLC (RPC C2/C18 SC
2.1/10 column) using a SMART system, and the radioactivity of each fraction
was plotted versus the eluted fractions. We observed similar results when the
reactionmixturewas digestedwith trypsin. This experiment is representative
of three independent experiments.
FIGURE 4. GGPP binding to RGGT. The prenylation mixture (20 l) contains
REP1 (2 M), RGGT (100 nM), Rab1a (4 M) substrate, and GGPP (2 M), and as
indicated on the graph 100 M ()-3-IPEHPC. After 30 min at 37 °C, 2 l of
polyclonal anti-RGGT (H492) and 25 l of protein G beads were added to the
reaction mixture and gently agitated for 2 h at 4 °C. The beads were washed
with phosphate-buffered saline and the immunocomplexes were precipi-
tated. GGPPmolecules associatedwith RGGTwere recovered in the superna-
tant anddetected by scintillation counting. Backgroundof the reaction (solu-
tion without RGGT) was removed from each observed condition. Data
represent the mean of four different experiments.
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binding site. The inhibitor did not compete for the RGGT-
bound GGPP in the absence of Rab protein, or in the presence
of Rab1a-CS, indicating that it does not preclude the binding of
GGPP to RGGT (Fig. 4). These results strongly suggest that the
inhibitor binds to a site that is distinct from the GGPP-binding
site on RGGT. Interestingly, when inhibitor and Rab1a-CC
were both incubated with the enzyme, RGGT-bound GGPP
could now be elicited (Fig. 4). This result suggests that the pres-
ence of inhibitor with Rab1a-CC leads to freezing of GGPP on
the RGGT-binding site, as when Rab1a-CS is present (in the
absence of inhibitor). In both cases, the presence ofGGPP stuck
on RGGT may reflect an inhibition of GG transfer due to an
inability of the monoprenylated Rab protein to move to a sec-
ond site on RGGT, which accepts a newly transferred
GG-cysteine.
Prenylation and Localization of Doubly Prenylated Rab Pro-
teins Is Disrupted by PCs in 293 Cells—To assess whether the
susceptibility of Rabs with different C-terminal motifs to inhi-
bition by PCs in intact cells matched the in vitro assays, we
transfected 293 cells with GFP-Rab constructs (Rab1A, Rab5,
Rab6, and Rab18) and analyzed the ability of 3-PEHPC to
inhibit prenylation in vivo and disrupt the localization of these
Rab proteins (Fig. 5). Accordingly, we found that prenylation of
GFP-Rab1a, GFP-Rab5a, and GFP-
Rab6a was susceptible to inhibition
by 3-PEHPC, as evidenced by their
significant shift from the detergent
phase (prenylated forms) to the
aqueous phase (unprenylated form)
upon Triton X-114 partitioning of
cell lysates (Fig. 5A). In this experi-
ment, the overexpression leads to
the presence of a proportion of
GFP-Rab in the aqueous phase even
at steady-state. Moreover, 1 mM
3-PEHPC completely prevented the
specific membrane targeting of
Rab1a, Rab6a, and Rab5a, resulting
in a diffuse cytoplasmic localization
of these Rabs (Fig. 5B), without
affecting the growth or viability of
the cells over this culture period
(data not shown). Reflecting the
enzyme inhibition data, the order of
potency for inhibition of prenyla-
tion by 3-PEHPC was Rab5a 
Rab1a Rab6. In contrast, both the
prenylation and subcellular localiza-
tion of the mono-prenylated, CAAX
motif-containing Rab18, was resist-
ant to 3-PEHPC treatment, in agree-
ment with the enzyme assays. Fur-
thermore, despite containing aCAAX
motif, the prenylation and subcellular
localization of Rab18 was also unaf-
fected by GGTI-298, a specific inhib-
itor of GGT-I (data not shown).
Order of Prenyl Addition on Rab
Proteins—Two previous studies examined the order of GG
addition byRGGTandproposed that theN-terminal cysteine is
preferred to the C-terminal one (16, 21). However, the sub-
strates used in those studies were single cysteine mutants of
Rab1a and a fluorescent derivative of GGPP, respectively, and
not native substrates. Because PCs specifically block only the
second event of prenylation, they are useful tools to character-
ize the first event of Rab prenylation.We took advantage of the
fact that the ICMT can only methylate the C-terminal gera-
nylgeranylated cysteine in a CAAX or CXCmotif and not in the
context of a CC motif (14). Using a coupled prenylation/meth-
ylation assay in vitro, we observed as expected, methylation of
the Rab1a-SCmutant but not of the Rab1a-CS mutant or wild-
type Rab1a-CC (Fig. 6), which is consistent with double preny-
lation of the CC motif, as previously reported (14). Further-
more, the Rab1a-SC mutant was methylated by ICMT in the
presence or absence of inhibitor, confirming the recognition of
this motif by the methyltransferase and validating the experi-
mental approach. Note that the inhibitor concentration used in
the experiment (100 M) was below the IC50 for Rab1a-CS or
SC mutants and therefore would have had little effect on the
prenylation reaction. Treatment with ()-3-IPEHPC did not
lead to increasedmethylation of Rab1a-CC, indicating that pre-
FIGURE5.Prenylationand localizationofGFP-Rabconstructswasanalyzed following transfectionof293
cells.A, transfected 293 cellswere treatedwith 0–1mM3-PEHPC for 18h, thenprenylated (detergent phase;D)
and unprenylated proteins (aqueous phase; A) were separated by Triton X-114 fractionation and GFP-Rabs
detected by Western blotting using an antibody to GFP. B, transfected 293 cells were treated with () or
without () 1mM3-PEHPC for 18 h, then subcellular localization of GFP-Rabs assessedby confocalmicroscopy.
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nylation of the N-terminal cysteine is not affected by the inhib-
itor. Furthermore, when the Rab1a-CSC mutant was treated
with ()-3-IPEHPC, we observed a dramatic reduction in
methylation compared with the untreated reaction, indicating
that prenylation of the C-terminal cysteine is inhibited by ()-
3-IPEHPC, i.e. this is the second prenylation step. Similar
experiments with wild-type Rab27a (CGC) showed identical
results (data not shown). These results demonstrate that the
N-terminal cysteine in dual-prenylatedRabs is preferred for the
first GG addition.
DISCUSSION
We report here a mechanism of action for inhibition of
RGGT by PCs. Our data suggests that these inhibitors act as
partial inhibitors of the geranylgeranylation reaction, effec-
tively inhibiting only the second GG addition onto those Rab
substrates that contain double cysteine motifs at their C termi-
nus. Yet, these behave as effective inhibitors in cell studies pre-
sumably for two reasons. One is that the majority of Rabs are
doubly geranylgeranylated and the second is that the enzyme
exhibits highest affinity for mono-prenylated intermediates in
the reaction (16), raising the possibility that these inhibitors
sequester the cellular pools of the enzyme in non-productive
complexes. Additionally, mono-geranylgeranylation of nor-
mally di-geranylgeranylated Rabs, such as Rab5, leads to
mistargeting to the endoplasmic reticulum, and loss-of-func-
tion (17). Therefore, even if a proportion of inhibitor-induced
mono-GG Rabs were able to interact with membranes, they
would not be present at the correct cellular location.
A limiting factor to mechanistic studies until now has been
the relatively low affinity of 3-PEHPC, the previously reported
PC inhibitor of RGGT (10). In this work, we took advantage of a
newly synthesized PC derivative, ()-3-IPEHPC, which we
found to be substantially more potent (25-fold) than 3-PE-
HPC at inhibiting RGGT for all the Rab substrates that we
tested. The kinetic characterization of RGGT inhibition by
these PCs revealed that both compounds are uncompetitive
inhibitors with respect to the Rab protein substrate andmixed-
type inhibitors with respect to GGPP. We then investigated in
more detail themechanismof inhibition. Using Rab1aC-termi-
nal mutants (CSC, CCS, CS, and SC), we observed that in the
presence of the singly prenylated substrates, the efficacy of inhi-
bition was severely impaired. Moreover, the prenylation of Rab
proteinswith aCAAXmotif (Rab13, Rab18, andRab23) was not
inhibited by ()-3-IPEHPC. We hypothesized that only the
second event of prenylation is targeted by the PCs and we ver-
ified the state of Rab1a and Rab27a prenylation after treatment
with PCs. In both cases, the prenylated substrates were modi-
fied on a single cysteine, demonstrating that the inhibitors
block the second addition of GGPP.
What could be the molecular basis for the inhibition of the
second GG transfer? One possibility is that the inhibitors could
be interfering with the complex rearrangements that must
occur on the active site of RGGT before the prenylation of the
second cysteine to remove the first prenyl-cysteine and allow
the alignment of that second cysteine with the newly bound
second GGPP substrate. Interestingly, Beese and colleagues
(22, 23) described several reaction intermediates in the FT and
GGT-I reactions that allowed us to create amodel for the inhib-
itory mechanism. These authors showed that soaking FT:pre-
nylated peptide orGGT:prenylated peptide crystalswith FPPor
GGPP, respectively, led to themovement of the prenylated cys-
teine from the active site to a new binding site in a solvent
accessible groove, instead of dissociation from the enzymes (22,
23). The authors further proposed that a similar process could
occur in the RGGT reaction where the first GG-cysteine could
be translocated to a nearby second site, allowing the secondGG
transfer to proceed (22). Our present studies raise the hypoth-
esis that the PC inhibitors bind to this second site for the fol-
lowing reasons. First, experiments measuring the binding of
GGPP to RGGT showed that the inhibitors do not preclude
GGPP binding and thus suggest that the inhibitors do not bind
to the GGPP-binding site. Second, the same experiments
showed that the presence of inhibitor frozeGGPP in its binding
site suggesting that it is inhibiting GGPP transfer by preventing
its movement away from the GGPP-binding site. Third, the
uncompetitive kinetics vis a` vis Rab substrates suggest that the
inhibitors do not bind to the peptide-binding site.
The mechanism of RGGT inhibition by 3-PEHPC has been
studied using a fluorescent analog of GGPP (NBD-FPP) and
Rab7a (ending in CXC) in a continuous fluorimetric assay (21).
Strikingly, the authors observed that the use of NBD-FPP led to
the formation of predominantly mono-prenylated Rab7, and
not doubly prenylated as observed using the native substrate
(24). This inability of NBD-FPP to be used in the second GG
addition suggests an obvious reason for the discrepancies
between the studies. Furthermore, the present studies suggest
that this behavior of NBD-FPP may be related to an inability to
bind the putative second site onRGGT. Recently, another study
reported on the identification of novel RGGT inhibitors (25).
These inhibitors appear to act via a different mechanism, prob-
FIGURE6.OrderofprenyladditiononRab1a.ThemethylationofRab1awas
measured after in vitro prenylation of the protein treated with (100 M) or
without ()-3-IPEHPC (for 30 min at 37 °C). 10 M [3H]S-adenosylmethionine
(specific activity  650 dpm/pmol) and 1 g of enriched ICMT membranes
were added to the reaction mixture for 45 min. Proteins were precipitated
and the incorporated radioactivity was measured. This experiment is repre-
sentative of two other independent experiments.
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ably binding to the peptide site as they exhibit competitive
kinetics with respect to Rab and uncompetitive kinetics with
respect to GGPP. Nevertheless, all effective inhibitors of this
class required a hydrophobic tail, suggesting the possibility that
binding to the putative second site may also be a feature of the
inhibitory mechanism of these compounds.
Our results imply that the prenylation mechanism for singly
and doubly prenylated Rab proteins may be different. Indeed,
the prenylation of Rab5a-CVLL is not inhibited by PCs,
whereas the prenylation of Rab5a-CCVLL is inhibited. The
present data suggests that non-productive ESI complexes do
not form in the presence of Rab-CAAX substrates, and
RGGT is able to dissociate from the mono-GG-Rab after
prenylation. In these cases, the AAX peptide appears to be of
importance because Rab1a-SC or Rab1a-CS are sensitive to
inhibition, albeit at high concentrations of the inhibitors
(200-fold increase compared with Rab1a WT proteins),
whereas Rab-CAAX substrates are resistant. One possibility is
that the AAX tail may prevent the use of the putative second
site, which would allow the ready release of the product from
the enzyme. Further work will be necessary to understand the
molecular basis for these differences.
Finally, we utilized the ability of PCs to inhibit the second
event of prenylation to demonstrate that the N-terminal cys-
teine of doubly prenylated Rabs is preferred for the first event.
This is in agreement with our previous report using Rab1a-CS
and Rab1a-SC substrates showing that the N-terminal cysteine
ismore efficiently prenylated than theC-terminal cysteine (16).
Moreover, it was reported the first event of Rab7 prenylation
was slower than the second one (26) and the prenylation of a
Rab7-SXC mutant was 3-fold faster than a Rab7-CXS mutant
event (21), suggesting the N-terminal cysteine being somewhat
preferred for the first prenylation event. We took advantage of
the fact that ICMT can only methylate prenylated cysteine
when present at the extreme C terminus (14, 27). Here, we
observed that Rab1a-CC andRab1a-CSC substrates in the pres-
ence of inhibitor are not methylated by ICMT (Fig. 6), which
strongly suggests that the N-terminal cysteine of double cys-
teine-containing Rabs is preferentially prenylated.
In summary, we have characterized the mechanism of RGGT
inhibition by the PC compounds, ()-3-IPEHPC and 3-PEHPC.
These inhibitors do not prevent the substrates binding to RGGT,
but block the second event of prenylation possibly by binding to a
second prenyl-binding site, to which the first prenyl-cysteine
moves into to allow the second GG addition. Crystallization of
3-IPEHPCRGGT and/or 3-IPEHPCREPRGGTRab complexes
should reveal this putative binding site and the reaction transition
states during the complex double geranylgeranylation reaction of
Rab proteins. These inhibitors might represent useful novel ther-
apeutic agents in Rab-mediated diseases.
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